Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672 · View on ClinicalTrials.gov ↗
Study Summary
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medication, pembrolizumab, approved for the treatment of melanoma skin cancer in adults, and to observe any similarities, or differences, in how the study drugs work in adolescent participants compared with adult participants. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Cemiplimab
- DRUG Fianlimab
Study Locations (20)
Buenos Aires
- DIABAID - Instituto de Asistencia Integral en Diabetes — Ciudad Autonoma de Buenos Aires
- Centro Medico Austral — Ciudad Autonoma de Buenos Aires
- Centro de Investigacion Pergamino — Pergamino
California
- UC San Diego — La Jolla
- The Angeles Clinic and Research Institute — Los Angeles
Other
- Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion) — Buenos Aires
- Exelsus — San Miguel de Tucumán
Queensland
- Gold Coast Hospital and Health Service — Southport
- Townsville University Hospital — Townsville
Victoria
- Andrew Love Cancer Centre — Geelong
- Alfred Hospital — Melbourne
Florida
- Orlando Health — Orlando
Ohio
- Seidman Cancer Center — Cleveland
Tennessee
- University of Tennessee Medical Center — Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,546 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2031-09-16 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05352672
The ClinicalTrials.gov registry entry for NCT05352672 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 290 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05352672 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Buenos Aires, California, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05352672 about?
NCT05352672 is a clinical study titled "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma". This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a t...
What is the current status of trial NCT05352672?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,546 participants. The study started on 2022-07-14. Estimated completion is 2031-09-16.
What conditions does trial NCT05352672 study?
This clinical trial studies the following conditions: Melanoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05352672?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Cemiplimab (DRUG), Fianlimab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05352672?
This trial is sponsored by Regeneron Pharmaceuticals, which has 290 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05352672 being conducted?
This trial has 20 study locations across California, Florida, Ohio, Tennessee, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.